| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant treatment for melanoma in clinical practice – Trial versus reality
|
de Meza, Melissa M.
|
|
|
158 |
C |
p. 234-245
|
artikel
|
| 2 |
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)
|
Campone, Mario
|
|
|
158 |
C |
p. 169-180
|
artikel
|
| 3 |
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
|
Galot, Rachel
|
|
|
158 |
C |
p. 17-26
|
artikel
|
| 4 |
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)
|
Maluf, Fernando C.
|
|
|
158 |
C |
p. 63-71
|
artikel
|
| 5 |
Bariatric surgery in a testicular cancer survivor: Restoring both metabolic and testosterone status
|
Volders, Ellen L.D.
|
|
|
158 |
C |
p. 12-14
|
artikel
|
| 6 |
Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis
|
Gracie, Lara
|
|
|
158 |
C |
p. 191-207
|
artikel
|
| 7 |
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
|
Larroquette, Mathieu
|
|
|
158 |
C |
p. 47-62
|
artikel
|
| 8 |
Comparing the performance of the palliative prognostic (PaP) score with clinical predictions of survival: A systematic review
|
Stone, Patrick
|
|
|
158 |
C |
p. 27-35
|
artikel
|
| 9 |
Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era
|
Araujo, Daniel V.
|
|
|
158 |
C |
p. 85-98
|
artikel
|
| 10 |
Corrigendum to ‘The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer’ [European Journal of Cancer 154 (2021) 175-189]
|
Le Du, Fanny
|
|
|
158 |
C |
p. 255
|
artikel
|
| 11 |
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
|
Eggermont, Alexander MM.
|
|
|
158 |
C |
p. 156-168
|
artikel
|
| 12 |
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis
|
Gaillard, T.
|
|
|
158 |
C |
p. 181-188
|
artikel
|
| 13 |
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF V600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
|
Zimmer, Lisa
|
|
|
158 |
C |
p. 72-84
|
artikel
|
| 14 |
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d’Etude des Tumeurs Uro-Génitales)
|
Cancel, Mathilde
|
|
|
158 |
C |
p. 1-11
|
artikel
|
| 15 |
Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation
|
Chanson, Noémie
|
|
|
158 |
C |
p. 208-216
|
artikel
|
| 16 |
Immune checkpoint inhibitors for cancer and venous thromboembolic events
|
Gong, Jingyi
|
|
|
158 |
C |
p. 99-110
|
artikel
|
| 17 |
Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial
|
Issels, Rolf D.
|
|
|
158 |
C |
p. 123-132
|
artikel
|
| 18 |
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma
|
Weber, Jeffrey S.
|
|
|
158 |
C |
p. 225-233
|
artikel
|
| 19 |
Letter comments re: Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A NCDB analysis
|
Jonas, Eduard
|
|
|
158 |
C |
p. 36-37
|
artikel
|
| 20 |
Letter re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer
|
Zhai, Lu-Lu
|
|
|
158 |
C |
p. 246-247
|
artikel
|
| 21 |
Letter to Editor, Re: The first report on Covid-19 vaccine refusal by cancer patients in Italy: Early data from a single-institute survey
|
Villarreal-Garza, Cynthia
|
|
|
158 |
C |
p. 189-190
|
artikel
|
| 22 |
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment
|
Cucchetti, Alessandro
|
|
|
158 |
C |
p. 133-143
|
artikel
|
| 23 |
Refractive changes during immunotherapy: Think diabetes!
|
Benassaia, Erwin
|
|
|
158 |
C |
p. 15-16
|
artikel
|
| 24 |
Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey
|
Di Noia, Vincenzo
|
|
|
158 |
C |
p. 253-254
|
artikel
|
| 25 |
Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer
|
Rasmussen, Louise S.
|
|
|
158 |
C |
p. 248-250
|
artikel
|
| 26 |
Re: The first report on coronavirus disease 2019 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey
|
Cavanna, Luigi
|
|
|
158 |
C |
p. 251-252
|
artikel
|
| 27 |
The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer
|
Cibula, David
|
|
|
158 |
C |
p. 111-122
|
artikel
|
| 28 |
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry
|
Ruste, Valentine
|
|
|
158 |
C |
p. 217-224
|
artikel
|
| 29 |
Trajectories of health-related quality of life and psychological distress in patients with colorectal cancer: A population-based study
|
Qaderi, Seyed M.
|
|
|
158 |
C |
p. 144-155
|
artikel
|
| 30 |
Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma
|
Shankar, Ananth
|
|
|
158 |
C |
p. 38-46
|
artikel
|
Tijdschrift beschrijving